Is EDIT or ELVN more undervalued in 2026?

CirclFi compares Editas Medicine, Inc. (EDIT) and Enliven Therapeutics, Inc. (ELVN) using 13 institutional-grade valuation models. EDIT has a Quality of Company score of 6.5/10 while ELVN scores 3.8/10.

Which is a better buy — EDIT or ELVN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EDIT and ELVN valuations compare?

EDIT at $3.43 and ELVN at $40.65 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EDIT vs ELVN Valuation Comparison 2026 — Intrinsic Value Analysis

EDIT

Biotechnology

Editas Medicine, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$3.43

Last close

Models

9/13

Active

ELVN

Biotechnology

Enliven Therapeutics, Inc.

Quality

3.8

out of 10

Value Trap

LOW

Price

$40.65

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	EDIT Fair Value	EDIT Upside	ELVN Fair Value	ELVN Upside
Bayesian DCF	Intrinsic	$1.15	-66.4%	$13.43	-67.0%
Earnings Power Value	Intrinsic	—	—	$20.47	-53.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.28	-62.7%	$6.06	-85.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EDIT vs ELVN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EDIT vs ELVN — Which Stock Is More Undervalued?

EDIT scores higher with a 6.5/10 quality rating vs ELVN's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Editas Medicine, Inc. (EDIT) and Enliven Therapeutics, Inc. (ELVN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EDIT currently trades at $3.43 with a QOC of 6.5/10, while ELVN trades at $40.65 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).